Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Frequently asked questions
What sector does Genmab A/S (0MGB) operate in?
Genmab A/S belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Genmab A/S (0MGB) current stock price?
As of the latest data, Genmab A/S stock price is DKK 2,096.00, with a previous close of DKK 2,096.00.
What is Genmab A/S (0MGB) current market capitalization?
Genmab A/S market cap is approximately 136.90 billion.
What is Genmab A/S (0MGB) Earnings Per Share (EPS)?
The trailing EPS is DKK 70.77.
What is Genmab A/S (0MGB) Price-to-Earnings (P/E) ratio?
Genmab A/S current P/E ratio is 29.62.
Does Genmab A/S (0MGB) pay dividends?
No. Genmab A/S does not pay a dividend.
When is Genmab A/S (0MGB) next earnings report?
Genmab A/S is expected to release its next earnings report on September 30, 2026.
What is Genmab A/S (0MGB) beta (volatility) score?
Genmab A/S has a beta of 0.644, indicating lower volatility than the overall market.
Unfortunately, you do not have access to this data. Make sure you have an active subscription.
